GlassScriptPhysician profile
Jaspreet S Johal
NPI 1457845877
$2,376.05
in general payments reported to CMS, 2019-2025
28 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $123 · 2021: $456 · 2022: $125 · 2023: $214 · 2024: $494 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Debt Forgiveness: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.90 |
| Debt Forgiveness | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.21 | 2021-2025 | |
| Ucb, INC. | $176.53 | 2019-2025 | Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $155.38 | 2024-2025 | Ultomiris |
| Eisai INC. | $153.26 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $137.86 | 2021-2023 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Esperion Therapeutics, INC. | $123.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $99.01 | 2021 | |
| Sk Life Science, INC. | $85.06 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $77.20 | 2025 | |
| Lundbeck LLC | $68.14 | 2023-2025 | Vyepti |
| Tg Therapeutics, INC. | $60.81 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $54.79 | 2025 | |
| Chiesi USA, INC. | $51.85 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $45.44 | 2024 | Keveyis |
| Neurelis, INC. | $41.11 | 2024 | Valtoco |
| Livanova USA, INC. | $37.35 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $35.76 | 2025 | |
| Baxter Healthcare | $35.61 | 2023-2024 | |
| Amgen INC. | $33.18 | 2023 | Aimovig |
| Takeda Pharmaceuticals U.S.A., INC. | $31.54 | 2025 | Hyqvia |
| Ani Pharmaceuticals, INC. | $27.53 | 2025 | Purified Cortrophin Gel |
| Biogen, INC. | $25.88 | 2024 | Vumerity, Tysabri |
| Vanda Pharmaceuticals INC. | $21.23 | 2025 | Ponvory |
| Lilly USA, LLC | $21.08 | 2025 | Kisunla |
| Acadia Pharmaceuticals INC | $20.64 | 2025 | Nuplazid |
| Argenx US, INC. | $13.60 | 2024 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Johal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.